[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381027-105":59,"doc-detail-381027-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","new-strategies-for-endometrial-cancer-detection-and-management","New Strategies for Endometrial Cancer Detection and Management","","New strategies for endometrial cancer detection and management are discussed, emphasizing the high worldwide burden and the limitations of standard early-stage care based on surgery, radiotherapy and/or chemotherapy. The editorial highlights the need for molecular targets to refine prognosis and guide therapeutic decisions, including gaps in steroid hormone receptor assessment. It reviews emerging biomarkers and diagnostic approaches, including bioinformatics on NRAS, proteomic findings on SBSN, serum-based prediction of lymph node metastasis, and the Cancer Genome Atlas molecular subgroups, alongside noninvasive vibrational biospectroscopy in early-stage screening.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-strategies-for-endometrial-cancer-detection-and-management/381027/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-strategies-for-endometrial-cancer-detection-and-management/381027.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is there an unmet medical need in endometrial cancer management?","Question",{"text":112,"@type":113},"Standard management for early-stage disease relies on surgery, radiotherapy and/or chemotherapy, and effective molecular targeting is still needed to improve classification for prognosis and treatment choice.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What emerging biomarkers or molecular signals are highlighted?",{"text":117,"@type":113},"The text cites NRAS gene deregulation for prognostic significance, a proteomic marker SBSN as a potential biomarker, and pathway alterations related to metastasis involving PTEN loss and related signaling events.",{"name":119,"@type":110,"acceptedAnswer":120},"How does vibrational biospectroscopy relate to endometrial cancer detection?",{"text":121,"@type":113},"Vibrational biospectroscopy is presented as a noninvasive, objective technique using light–tissue interactions to obtain chemical information, aiming to support screening and detection of pre-cancer/early cancer and metastatic lymph node involvement, though it remains in trial phases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},381027,1791481833,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Editorial  \nNew Strategies for Endometrial Cancer Detection and Management  \nLaura Paleari   \nCitation: Paleari, L. New Strategies for Endometrial Cancer Detection and Management. Int. J. Mol. Sci. 2023, 24, 6462. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms24076462](10.3390/ijms24076462)  \nReceived: 20 March 2023  \nAccepted: 27 March 2023  \nPublished: 30 March 2023  \nCopyright: © 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nResearch, Innovation and HTA Unit, A.Li.Sa., Liguria Health Authority, 16121 Genoa, Italy; [laura.paleari@alisa.liguria.it](laura.paleari@alisa.liguria.it); Tel.: +39-010-5484243  \nWith 400,000 new cases and over 80,000 deaths a year worldwide, endometrial cancer (EC) holds a rather unfortunate record, namely, that of the tumour with the highest increase in incidence, a unique trend among gynaecological cancers [1] . EC is more common in high-income countries where obesity rates are high, and this cancer is the fourth most common malignancy in women. It mainly affects postmenopausal women, where patients'mean age at diagnosis is 61 years, and most cases are diagnosed in women aged 45 to 74 years [1] . The prognosis is worse in older patients with higher-grade and more prevalent tumours, with a median 5-year survival rates of 95% for stage I/II and of 60% for stage III/IV. Overall, 63% of patients are tumour free 􀀕5 years after therapy [1] .  \nTo date, the standard management of early-stage cancer includes surgery, radiotherapy and/or chemotherapy. Thus, there is a clear unmet medical need for disease management, and it is essential to find a molecular target to better classify ECs in terms of prognosis and to drive the therapeutical choice. The intention of this Special Issue is to increase our understanding of EC development, which may lead to the discovery of new molecular diagnostic technologies and targeted therapeutics. For instance, although EC is a hormone-dependent neoplasm, there are no recommendations for the determination of steroid hormone receptors [2] . Currently, only a few studies have assessed the impact hormonal therapy (HT) has in EC treatment, suggesting how HT is a useful treatment modality to prolong progressionfree survival (PFS) and overall survival (OS) [3] . Recently, several studies have assessed diagnostic and therapeutic markers. Bioinformatics analyses indicated that NRAS gene deregulation affected the OS rate of patients with EC, leading to prognostic significance [4] . Celsi and colleagues with a gel-based proteomic assay showed that suprabasin (SBSN), an oncogene previously associated with poor prognosis in different cancers, could be a potential novel biomarker in EC [5] . Interestingly, the study of Benbrook et al. analysed serum from EC patients (with or without lymph node metastases, and compared with that of benign gynaecological surgery patients) to determine if it is possible to predict the presence of positive lymph nodes, which represents a critical factor guiding treatment decisions [6] . The results suggest that pathways implicated in metastases included the loss of PTEN, PI3K, AKT and PKA activation, leading to calcium signalling, oxidative phosphorylation and oestrogen receptor-induced transcription, platelet activation, the epithelial-to-mesenchymal transition, and senescence. Upstream activators implicated in these events included neurostimulation and inflammation, the activation of G-proteincoupled receptor G􀀌􀀍, the loss of HER-2 activation and the upregulation of the insulin receptor [6] .  \nMoreover, advancements have newly been made in EC pathological classification through the new molecular classification that allows for a more accurate c","cbCaiqidhEvsq0aP","https://ap.wps.com/l/cbCaiqidhEvsq0aP","pdf",184816,"English","# Editorial Focus\n## Unmet Need and Molecular Targets\n## Hormonal Therapy and Emerging Markers\n## Molecular Classification and Precision Diagnostics\n## Vibrational Biospectroscopy for Screening and Diagnosis","[{\"question\":\"Why is there an unmet medical need in endometrial cancer management?\",\"answer\":\"Standard management for early-stage disease relies on surgery, radiotherapy and/or chemotherapy, and effective molecular targeting is still needed to improve classification for prognosis and treatment choice.\"},{\"question\":\"What emerging biomarkers or molecular signals are highlighted?\",\"answer\":\"The text cites NRAS gene deregulation for prognostic significance, a proteomic marker SBSN as a potential biomarker, and pathway alterations related to metastasis involving PTEN loss and related signaling events.\"},{\"question\":\"How does vibrational biospectroscopy relate to endometrial cancer detection?\",\"answer\":\"Vibrational biospectroscopy is presented as a noninvasive, objective technique using light–tissue interactions to obtain chemical information, aiming to support screening and detection of pre-cancer/early cancer and metastatic lymph node involvement, though it remains in trial phases.\"}]","New Strategies for Endometrial Cancer Detection and Management | PDF",1790243223]